In support of this finding, RBM3 has been previously implicated in cancer and reported to be overexpressed in esophageal and gastric adenocarcinoma with particularly high expression in those cancers with a background of intestinal metaplasia (55, 56). Here, RBM3 is linked to gastric adenocarcinoma.